MERLIN-TIMI 36: Summary and implications

1
MERLIN-TIMI 36 Summary and implications

• In patients with ACS, ranolazine added to
  standard therapy was associated with
• No difference in composite efficacy endpoint of
  CV death, MI, or recurrent ischemia
• No difference in safety endpoints of all-cause
  death, all-cause death or CV hospitalization, or
  symptomatic documented arrhythmia
• Significant reduction in arrhythmias detected by
  Holter monitoring during first 7 days
• Findings do not support use of ranolazine in ACS
  but add to previous safety data and provide
  additional support for ranolazine as antianginal
  therapy in stable CAD

Morrow DA et al. JAMA. 20072971775-83.